Orbis Medicines

Executive Summary

Orbis Medicines, a Danish biotechnology company founded in 2021, is advancing next-generation oral macrocycle drugs to address the limitations of biologic therapies. Leveraging its proprietary nGen chemistry platform, the company systematically explores macrocycle chemical space to design 'nCycles'—compounds engineered for oral bioavailability and membrane permeability. This approach aims to provide oral alternatives to injectable biologics, targeting both intra- and extracellular targets. While still in early stages with no disclosed pipeline or funding details, Orbis Medicines represents an innovative player in the oral drug delivery space, with potential to transform treatment paradigms for chronic diseases requiring frequent injections.

Upcoming Catalysts (preview)

• 2026Series A or B financing round80% success
• 2026Preclinical proof-of-concept data for lead nCycle program60% success
• 2026-2027Partnership or collaboration with a larger pharma company50% success